Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma

Inclusion Criteria: * Confirmed diagnosis of MCL with CD20 and cyclin D1 positivity in tissue biopsy. * Ki-67 \>= 50%. * Patients must have never received any prior systemic therapy for their disease. * Sign (or their legally-acceptable representatives must sign) an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study. * Patients should in general have bi-dimensional measurable disease using the Cheson criteria (measurable disease by computed tomography \[CT\] scan defined as at least 1 lesion that measures \>= 1.5 cm in single dimension) (bone marrow or gastrointestinal \[GI\] only involvement is acceptable). * Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less. * Absolute neutrophil count (ANC) \>= 1000/mm\^3 without transfusion support. * Platelet count \> 100,000/mm\^3. Patients who have bone marrow infiltration by MCL are eligible if their platelet level is \>= 50,000 /mm\^3 independent of platelet transfusions. * Aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) and aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) =\< 3 x upper limit of normal. * Serum bilirubin \< 1.5 mg/dl unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin. * Creatinine (Cr) clearance \>= 25 mL/min (per Cockcroft-Gault equation). * Disease free of prior malignancies of equal to or greater than 6 months with exception…